Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AlphaCor: Clinical outcomes.

Celia R Hicks1, Geoffrey J Crawford, John K G Dart

  • 1Biomaterials Research Centre, Lions Eye Institute and Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia. crhicks@cyllene.uwa.edu.au

Cornea
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of allogeneic ocular surface stem cell transplantation.

Frontiers in ophthalmology·2026
Same author

Correcting motion-related B<sub>0</sub> inhomogeneities in magnetic resonance imaging via combined spherical harmonics and AC/DC matrix coils using DL-based prediction-simulation study.

Scientific reports·2026
Same author

Current Practices, Evolving Techniques, and Immunologic Challenges in Living and Deceased Donor Limbal Stem Cell Transplantation.

American journal of ophthalmology·2026
Same author

Neurotrophic Keratopathy: Current Concepts, Management, and Emerging Treatments.

Cornea·2026
Same author

Tacrolimus-Related Kidney Function Change in Ocular Stem Cell Transplantation.

Cornea·2026
Same author

Preoperative prediction of 5-ALA fluorescence in gliomas: comparison of 7-Tesla magnetic resonance spectroscopic imaging, contrast-enhancement on MRI, and positron emission tomography.

European radiology·2026
Same journal

Corneal Tissue Addition Keratoplasty.

Cornea·2026
Same journal

Corneal Tissue Addition Keratoplasty for Keratoconus: Point-Counterpoint.

Cornea·2026
Same journal

Posterior Segment Pressurization With Intravitreal Balanced Salt Solution to Stabilize Anterior Chamber Gas During Endothelial Keratoplasty.

Cornea·2026
Same journal

Central Corneal Thickness Six Postoperative Months After DMEK or Triple-DMEK.

Cornea·2026
Same journal

Rebubbling and Graft Detachment in Pre-Descemet Endothelial Keratoplasty: A Prospective Study.

Cornea·2026
Same journal

Letter Regarding: ESCALÓN: A Prospective Randomized Trial of Corneal Endothelial Cell Therapy in Subjects With Corneal Edema.

Cornea·2026
See all related articles

This study evaluates the long-term clinical performance and safety of the AlphaCor artificial cornea in patients who cannot receive traditional donor tissue transplants. Researchers analyzed data from over 300 implantations to determine device retention rates, common complications, and improvements in patient vision.

Area of Science:

  • Ophthalmology research within AlphaCor artificial cornea clinical medicine
  • Surgical outcomes research in visual health sciences

Background:

No prior work had fully characterized the long-term performance of artificial corneal implants in patients ineligible for standard donor grafting. That uncertainty drove the need for comprehensive prospective tracking of device retention and safety. It was already known that severe ocular surface disease often leads to permanent vision loss. Prior research has shown that traditional transplant methods frequently fail in these high-risk environments. This gap motivated a detailed assessment of synthetic alternatives designed for challenging clinical scenarios. Investigators required longitudinal data to understand how these devices behave over several years. Previous studies lacked the scale necessary to identify specific risk factors for device failure. That limitation hindered clinical decision-making for surgeons managing complex corneal blindness.

Purpose Of The Study:

The aim of this study is to evaluate the clinical outcomes and safety of AlphaCor artificial cornea implantation. Researchers sought to determine the effectiveness of this device for patients suffering from corneal blindness that cannot be treated by traditional donor grafting. The investigation addresses the performance of the implant in both protocol and off-label clinical scenarios. By analyzing longitudinal data, the team intended to identify key factors influencing device retention and patient success. They also aimed to document the incidence of common complications such as stromal melting and fibrous reclosure. Furthermore, the study explores the impact of adjunctive therapies, specifically medroxyprogesterone, on preventing adverse events. The authors intended to provide a clearer understanding of how previous ocular pathology affects postoperative visual improvement. This work serves to establish a baseline for the evolving surgical techniques and therapeutic strategies used with this synthetic technology.

Keywords:
artificial corneavisual acuitystromal meltingdevice retention

Frequently Asked Questions

The researchers report that the probability of device retention for protocol cases was 92% at six months, 80% at one year, and 62% at two years. Conversely, off-label cases demonstrated a significantly higher risk of failure compared to those following standard protocols.

The authors identify stromal melting, fibrous reclosure of the posterior lamellar opening, and white intraoptic deposits as the most frequent adverse events. In 2005, these issues occurred at rates of 11.4%, 5.1%, and 2.6%, respectively, among the study population.

The investigators propose that medroxyprogesterone acts as a protective agent against stromal melting. This finding is supported by a statistically significant P-value of 0.001, distinguishing treated cases from those lacking this specific adjunctive therapy.

The study utilized prospective preoperative and follow-up records from 322 implanted devices. This longitudinal dataset allowed for the statistical evaluation of trends and associations using SPSS software, covering a maximum follow-up period of 7.4 years.

Related Experiment Videos

Main Methods:

The review approach involved collecting prospective preoperative and follow-up information for all 322 implanted devices. Researchers utilized statistical software to analyze outcomes, trends, and associations within the gathered patient records. The investigation covered a maximum follow-up duration of 7.4 years, with a mean in situ period of 15.5 months. This design allowed for the comparison of protocol cases against off-label applications. The team tracked specific complications, including stromal melting and intraoptic deposits, to assess device safety. They also monitored visual acuity changes from preoperative baseline levels to postoperative status. The study incorporated data returned through February 2006 to ensure a comprehensive overview of clinical performance. This methodology focused on identifying factors that influence long-term device retention and patient success.

Main Results:

The strongest finding indicates that the probability of device retention for protocol cases reached 92% at six months, 80% at one year, and 62% at two years. Off-label cases faced a higher risk of failure, with a P-value of 0.010. Cases not receiving medroxyprogesterone also showed increased risk, indicated by a P-value of 0.001. The most frequent complications in 2005 were stromal melting at 11.4%, fibrous reclosure at 5.1%, and white intraoptic deposits at 2.6%. Loss of an eye occurred in only 1.3% of all cases. Mean visual acuity improved by two lines postoperatively, moving from hand movements to a range of light perception to 20/20. History of glaucoma or the presence of tubes did not negatively impact the retention of the implant. Patients with a history of herpetic keratitis did not experience an increased risk of failure.

Conclusions:

The authors propose that this synthetic implant serves as a viable alternative when standard donor tissue is unlikely to succeed. They suggest that the device maintains anatomical integrity, allowing for potential future reversal to donor grafting if necessary. The researchers observe that adjunctive therapies, such as the use of medroxyprogesterone, appear to mitigate specific risks like stromal melting. They note that while complications occur, they rarely lead to total loss of the eye. The team emphasizes that surgical techniques continue to improve as clinicians gain more experience with the procedure. They conclude that ongoing data collection remains vital for refining the role of this technology in ophthalmology. The findings indicate that patient history, such as previous herpetic keratitis, does not necessarily preclude successful outcomes. The report highlights the importance of standardized protocols to optimize long-term retention rates for these patients.

The team measured visual acuity improvements, noting a mean gain of two lines postoperatively. While preoperative vision was limited to hand movements, postoperative results ranged from light perception to 20/20, depending on the patient's prior pathology and recovery course.

The researchers suggest that the device provides a treatment path for severe conditions where donor grafts fail. They imply that the ability to reverse the procedure to a donor graft maintains anatomical integrity, offering a safety net for patients experiencing complications.